Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries, was featured in a recent episode of the Stock Day podcast. In the podcast, PBIO president and CEO Richard Schumacher the company’s recent nanoemulsion achievements with podcast host Everett Jolly. During the interview, Schumacher stated that the company recently transformed the potent antioxidant astaxanthin into a water-soluble compound, noting that astaxanthin, the most powerful nutritional antioxidant known to humans, is in short supply and is not easy to obtain. The substance is extracted from algae in an oil, and because it is an oil, the human body has problems absorbing it. “The solution lies in finding ways to get them to mix and stay in solution,” said Pressure BioSciences president and CEO Richard Schumacher in the press release. “But even conventional emulsions and microemulsions of oils in water still allow vast numbers of the oil molecules to hide in the interior of the droplets, where they cannot be absorbed by our bodies. However, using Pressure BioSciences’ new high-pressure driven Ultra Sheer Technology(TM) platform, we were able to consistently and reproducibly nanoemulsify it into droplets so small that the oil becomes essentially water soluble, and the oily molecules are effectively all exposed at the surface of the oil droplet for easy access and absorption by our bodies.”
To view the full podcast, visit https://ibn.fm/WQrrr
To view the full press release, visit https://ibn.fm/gjDZ5
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) (“PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The company’s primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of the company’s pressure-based technologies in the following areas: (1) the use of PBIO’s recently acquired, patented technology from BaroFold Inc. to allow entry into the biopharma contract services sector and (2) the use of PBIO’s recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to prepare higher-quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information about the company, visit www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
